inhibition bet recruitment chromatin effective treatment mll-fusion leukaemia 
recurrent chromosomal translocations involving mixed lineage leukaemia mll gene initiate aggressive forms leukaemia often refractory conventional therapies many mll-fusion partners members super elongation complex sec critical regulator transcriptional elongation suggesting aberrant control process important role leukaemia induction use global proteomic strategy demonstrate mll fusions part sec polymerase-associated factor complex pafc associated bet family acetyl-lysine recognizing chromatin adaptor proteins data provided basis therapeutic intervention mll-fusion leukaemia via displacement bet family proteins chromatin show novel small molecule inhibitor bet family gsk1210151a i-bet151 profound efficacy human murine mll-fusion leukaemic cell lines induction early cell cycle arrest apoptosis i-bet151 treatment two human leukaemia cell lines different mll fusions alters expression common set genes whose function may account phenotypic changes mode action i-bet151 least part due inhibition transcription key genes bcl2 c-myc cdk6 displacement brd3/ pafc sec components chromatin vivo studies indicate i-bet151 significant therapeutic value providing survival benefit two distinct mouse models murine mll-af9 human mll-af4 leukaemia finally efficacy i-bet151 human leukaemia stem cells demonstrated providing evidence potent therapeutic potential findings establish displacement bet proteins chromatin promising epigenetic therapy aggressive leukaemias 
